Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine (BMPEA), 1,3-dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylbutylamine (1,3-DMBA) and higenamine

References

• Geller AI, Shehab N, Weidle NJ, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373(16):1531–1540.
   PubMed Web of Science ®Google Scholar
• Archer JRH, Dargan PI, Lostia AM, et al. Running an unknown risk: a marathon death associated with the use of 1,3-dimethylamylamine (DMAA). Drug Test Anal. 2015;7(5):433–438.
   PubMed Web of Science ®Google Scholar
• Cohen PA, Zeijlon R, Nardin R, et al. Hemorrhagic stroke probably caused by exercise combined with a sports supplement containing b-methylphenyl-ethylamine (BMPEA): a case report. Ann Intern Med. 2015;162(12):879–880.
   PubMed Web of Science ®Google Scholar
• Venhuis B, Keizers P, van Riel A, et al. A cocktail of synthetic stimulants found in a dietary supplement associated with serious adverse events. Drug Test Anal. 2014;6(6):578–581.
   PubMed Web of Science ®Google Scholar
• Cohen PA, Travis JC, Keizers PHJ, et al. Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). Clin Toxicol. 2018;56(6):421–426.
   PubMed Web of Science ®Google Scholar
• Walker SJ. Correspondence to Bo Zhu, President Syntech (SSPF) International. Inc. Food and Drug Administration., Dec 6, 2004.
   Google Scholar
• Zhao J, Wang M, Avula B, Khan IA. Detection and quantification of phenethylamines in sports dietary supplements by NMR approach. J Pharm Biomed Anal. 2018;151:347–355.
   PubMed Web of Science ®Google Scholar
• Avula B, Bae JY, Chittiboyina AG, et al. Liquid chromatography-quadrupole time of flight mass spectrometric method for targeted analysis of 111 nitrogen-based compounds in weight loss and ergogenic supplements. J Pharm Biomed Anal. 2019;174:305–323.
   PubMed Web of Science ®Google Scholar
• Pawar RS, Sagi S, Leontyev D. Analysis of bitter orange dietary supplements for natural and synthetic phenethylamines by LC-MS/MS. Drug Test Anal. 2020;12(9):1241–1251.
   PubMed Web of Science ®Google Scholar
• Anderson WG. The sympathomimetic activity of N-isopropyloctopamine in vitro. J Pharm Exp Ther. 1983;225(5):553–558.
   PubMed Web of Science ®Google Scholar
• Pilkington TRE, Lowe RD, Foster R, et al. Effect of sympathomimetic compounds with beta-adrenergic effects on plasma free fatty acids in man. J Lipid Res. 1966;7(1):73–76.
   PubMed Web of Science ®Google Scholar
• Marsh DF, Herring DA. The comparative pharmacology of the N-alkyl-1-(p-hydroxyphenyl)-2-aminoethanols. Arch Int Pharmacodyn. 1949;78(3):489–498.
   Google Scholar
• Weekers R, Collignon-Brach J. Etude comparative des effets de diverses amines sympathicomimetiques sur l’oeil. Acta Ophthal. 1966;44(5):762–777.
   Web of Science ®Google Scholar
• Korting GW, Rasp KF. Zur Pharmakologie der experimentellen Pilomotorenreaktion und deren lokaler Beeinflußbarkeit. Arzneimittel-Forschung. 1954;4(2):63–67.
   PubMed Web of Science ®Google Scholar
• Détérénol (DCI rec), Traitement de glaucome. In Index Nominum 1978. Zürich: le Centre Scientifique de la Société Suisse de Pharmacie; 1977. p. 237
   Google Scholar
• Zhu B Premarket notification for a new dietary ingredient: betaphrine. Sept, 17, 2004.
   Google Scholar
• Council on pharmacy and chemistry. New and nonofficial remedies: Vonedrine. JAMA. 1946;131(10):825.
   Web of Science ®Google Scholar
• Vonedrine with Ceepryn (solution). In Drug Topics Red Book 1944/1945. 48th ed. New York, NY: Topics Pub. Co; 1945. p. 355.
   Google Scholar
• Food and Drug Administration. New drug applications: notice of withdrawal of approval. Fed Regist. 1971;36(185):18885–18899.
   Google Scholar
• Rasmussen N, Keizers PHJ. History full circle: ‘Novel’ sympathomimetics in supplements. Drug Test Anal. 2016;8(3–4):283–286.
   PubMed Web of Science ®Google Scholar
• Cohen PA. DMAA as a dietary supplement ingredient. Arch Intern Med. 2012;172(13):1038–1039.
   PubMedGoogle Scholar
• Warren MR, Marsh DG, Thompson CR, Shelton RS, Becker TJ. Pharmacological studies on dl-β-phenyl-n-propylmethylamine, a volatile amine. J Pharm Exper Ther. 1943;79(3):187–199.
   Google Scholar
• Davis LC. Clinical study of Vonecidin. Laryngoscope. 1949;59(3):272–277.
   PubMed Web of Science ®Google Scholar
• Bumgardner JS, Abernethy LD, Zimmerman FB. Vonedrine (phenylpropylmethylamine). Clinical study of a new nasal decongestant. Laryngoscope. 1944;54(8):408–420.
   Google Scholar
• Stoughton RB, DeOreo G, Clendenning W. Effects of intradermal injection of vasopressors in normal and diseased human skin. Arch Dermatol. 1960;82(3):400–407.
   PubMedGoogle Scholar
• Glaser K. Phenyl-propyl-methylamine hydrochloride for asthma: a clinical study. Amer J Clin Med. 1944;51:63–65.
   Google Scholar
• da Justa Neves DB, Caldas ED. Determination of caffeine and identification of undeclared substances in dietary supplements and caffeine dietary exposure assessment. Food Chem Toxicol. 2017;105:194–202.
   PubMed Web of Science ®Google Scholar
• Lisi A, Hasick N, Kazlauskas R, Goebel C. Studies of methylhexaneamine in supplements and geranium oil. Drug Test Anal. 2011;3(11–12):873–876.
   PubMed Web of Science ®Google Scholar
• Cohen PA. The FDA and adulterated supplements - dereliction of duty. JAMA Netw Open. 2018;1(6):e183329.
   PubMed Web of Science ®Google Scholar
• Tucker J, Fischer T, Upjohn L, et al. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. JAMA Netw Open. 2018;1(6):e183337.
   PubMed Web of Science ®Google Scholar
• Cohen PA, Bloszies C, Yee C, Gerona R. An amphetamine isomer whose efficacy and safety in humans has never been studied, β-methylphenylethylamine (BMPEA), is found in multiple dietary supplements. Drug Test Anal. 2016;8(3–4):328–333.
   PubMed Web of Science ®Google Scholar
• Cohen PA, Maller G, DeSouza R, Neal-Kababick BS. Presence of banned drugs in dietary supplements following FDA recalls. Jama. 2014;312(16):1691–1693.
   PubMed Web of Science ®Google Scholar
• Cohen PA, Wen A, Gerona R. Prohibited stimulants in dietary supplements after enforcement action by the US Food and Drug Administration. JAMA Intern Med. 2018;178(12):1721–1723.
   PubMed Web of Science ®Google Scholar
• Cohen PA, Zakharevich I, Gerona R. Presence of piracetam in cognitive enhancement dietary supplements. JAMA Intern Med. 2020;180(3):458–459.
   PubMed Web of Science ®Google Scholar